- ISIN
- NL0010832176
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- May 18, 2017
Highlights
- Market Cap
- $59.83B
- Enterprise Value
- $56.43B
- EPS (TTM)
- $32.69
- PE Ratio
- 27.64
- PEG Ratio
- 0.53
- Total Revenue (TTM)
- $5.49B
- Gross Profit (TTM)
- $4.38B
- EBITDA (TTM)
- $1.50B
- Year Range
- $510.06 - $934.62
- Target Price
- $1,026.71
- ROA (TTM)
- 24.82%
- ROE (TTM)
- 29.43%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ARGX Performance Chart
argenx SE (ARGX) is up 7.5% since the beginning of the year. At $904 per share, ARGX is trading 3.3% below its 52-week high of $935. Investors who bought $1,000 worth of ARGX shares 5 years ago would now be looking at an investment worth $2,895.
Loading charts...
Returns By Period
argenx SE (ARGX) has returned 7.47% so far this year and 66.70% over the past 12 months.
argenx SE
- 1D
- 2.97%
- 1M
- 12.06%
- YTD
- 7.47%
- 6M
- 6.07%
- 1Y
- 66.70%
- 3Y*
- 31.62%
- 5Y*
- 23.69%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ARGX Monthly Returns History
Based on dividend-adjusted daily data since May 18, 2017, ARGX's average daily return is +0.22%, while the average monthly return is +4.45%. At this rate, an investment would double in approximately 1.3 years.
Historically, 60% of months were positive and 40% were negative. The best month was Dec 2017 with a return of +97.2%, while the worst month was Jan 2022 at -23.1%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ARGX closed higher 51% of trading days. The best single day was Dec 11, 2017 with a return of +78.9%, while the worst single day was Dec 20, 2023 at -25.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -0.05% | -8.75% | -4.78% | 7.05% | 6.94% | 8.11% | 7.47% | ||||||
| 2025 | 6.53% | -4.65% | -5.25% | 9.00% | -11.14% | -3.84% | 21.61% | 6.25% | 3.56% | 10.97% | 11.42% | -7.79% | 36.74% |
| 2024 | 0.02% | -0.13% | 3.61% | -4.63% | -1.19% | 15.91% | 19.96% | 0.28% | 4.79% | 8.16% | 5.16% | -0.25% | 61.66% |
| 2023 | 0.90% | -4.25% | 1.79% | 4.11% | 0.21% | 0.26% | 29.44% | -0.39% | -2.16% | -4.49% | -4.04% | -15.57% | 0.42% |
| 2022 | -23.11% | 6.85% | 9.59% | -8.88% | 7.65% | 22.50% | -3.87% | 3.75% | -6.57% | 9.88% | 2.59% | -4.81% | 8.18% |
| 2021 | -0.36% | 12.85% | -16.72% | 4.11% | -2.69% | 7.91% | 1.12% | 8.73% | -8.77% | -0.01% | -7.53% | 25.42% | 19.08% |
Benchmark Metrics
argenx SE has an annualized alpha of 56.09%, beta of 0.73, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since May 18, 2017.
- This stock captured 209.04% of S&P 500 Index gains but only 55.25% of its losses - a favorable profile for investors.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 56.09%
- Beta
- 0.73
- R²
- 0.07
- Upside Capture
- 209.04%
- Downside Capture
- 55.25%
Return for Risk
Risk / Return Rank
ARGX ranks 85 for risk / return — in the top 85% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for argenx SE (ARGX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ARGX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.17 | ||
| Sortino ratioReturn per unit of downside risk | +0.36 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.37 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 2.35 | 2.78 | -0.44 |
| Martin ratioReturn relative to average drawdown | 6.26 | 12.44 | -6.18 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the argenx SE. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the argenx SE was 38.20%, occurring on Dec 20, 2023. Recovery took 177 trading sessions.
The current argenx SE drawdown is 2.78%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2023 bear market2023 | -38.20%Dec 2023 | 4mo 29d | 8mo 20d | 1y 1moJul 2023 - Sep 2024 |
Rate-hike selloffLate 2018 | -36.29%Oct 2018 | 3mo 29d | 27d | 4mo 26dJun 2018 - Nov 2018 |
COVID crash2020 | -34.13%Mar 2020 | 2mo 6d | 2mo 11d | 4mo 17dJan 2020 - May 2020 |
Bear market2022 | -33.09%Jan 2022 | 11mo 19d | 5mo 9d | 1y 4moFeb 2021 - Jul 2022 |
2019 bear market2019 | -29.18%Oct 2019 | 2mo 21d | 1mo 27d | 4mo 18dJul 2019 - Dec 2019 |
Drawdown Indicators
| ARGX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.20% | -56.78% | +18.58% |
Max Drawdown (1Y)Largest decline over 1 year | -28.58% | -9.10% | -19.48% |
Max Drawdown (3Y)Largest decline over 3 years | -38.20% | -18.90% | -19.30% |
Max Drawdown (5Y)Largest decline over 5 years | -38.20% | -25.43% | -12.77% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -2.78% | -1.80% | -0.98% |
Average DrawdownAverage peak-to-trough decline | -11.06% | -10.71% | -0.35% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.69% | 2.03% | +8.66% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of argenx SE over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how argenx SE is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ARGX, comparing it with other companies in the Biotechnology industry. Currently, ARGX has a P/E ratio of 27.6. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ARGX compared to other companies in the Biotechnology industry. ARGX currently has a PEG ratio of 0.5. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ARGX relative to other companies in the Biotechnology industry. Currently, ARGX has a P/S ratio of 10.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ARGX in comparison with other companies in the Biotechnology industry. Currently, ARGX has a P/B value of 8.2. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ARGX
Add argenx SE to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ARGX